Contact lens maker Bausch + Lomb says it is exploring sale

Bausch + Lomb is considering a sale to aid parent Bausch Health's exit, amid private equity interest, following share volatility and earlier reports of a potential bid.

BofA reinstates pharma coverage

Bank of America reviews 11 U.S. pharma stocks, highlighting growth potential and challenges amid patent cliffs and pricing pressures while recommending buy, neutral, and underperform ratings.

Revance agrees to lower take-private offer by Crown Labs

Crown Laboratories will acquire Revance Therapeutics at a 50% lower price due to delays and disputes, causing a 20% stock drop for Revance.

AbbVie reports positive results in Parkinson's trial

AbbVie's Phase 3 TEMPO-2 trial for tavapadon showed significant improvement in motor function for early Parkinson's disease, advancing its potential as a first-in-class treatment.

Exclusive-Big hedge funds call on doctors, scientists for an edge on pharma, sources say

AbbVie, Nvidia Lead Friday's Market Cap Stock Movers

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69%

U.S. stocks rose on Monday, with the Dow reaching new heights; notable gains in Consumer Goods and Financial sectors, while some major players like Intel and Moderna faced declines.

AbbVie shares slip after schizophrenia drug trial misses primary endpoint

Trump 2.0 to be modest positive for BioPharma, BMO says, but watch FDA

BMO Capital Markets analysts predict Trump's presidency will positively impact the biopharma sector, despite concerns over potential healthcare appointees and tax policy uncertainties.

Earnings call: AbbVie raises outlook on strong Q3 performance, Skyrizi and Rinvoq growth